Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreBringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreAccelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreA curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTS"Discover the future through our enlightening podcasts available in the United States.
EXPLORE PODCASTSThis study explores the impact of The Inflation Reduction Act (IRA) of 2022 on 340B Modifiers. In August 2022, the IRA introduced provisions requiring the identification of 340B transactions. 340B modifiers — a system of codes used on some pharmacy and medical claims to identify 340B drugs — have been required by the Centers for Medicare & Medicaid Services (CMS) for Medicare Part B reimbursement, and more recently, to identify 340B drugs. Download this white paper for a deeper look into 340B Modifiers data and the impact it will have on the industry.
For a summary of this study and paper please see our fact sheet here
Gain high value access and increase the profitability of your brands
Rely on market-leading strategists to help you achieve maximum access and profitability